Literature DB >> 31964792

Ceftazidime-Avibactam Resistance Associated with Increased bla KPC-3 Gene Copy Number Mediated by pKpQIL Plasmid Derivatives in Sequence Type 258 Klebsiella pneumoniae.

Marco Coppi1, Vincenzo Di Pilato1, Francesco Monaco2, Tommaso Giani1, Pier Giulio Conaldi2,3, Gian Maria Rossolini4,5.   

Abstract

This study reports on the characterization of two ceftazidime-avibactam (CZA)-resistant KPC-producing Klebsiella pneumoniae strains (KP-14159 and KP-8788) sequentially isolated from infections occurred in a patient never treated with CZA. Whole-genome sequencing characterization using a combined short- and long-read sequencing approach showed that both isolates belonged to the same ST258 strain, had altered outer membrane porins (a truncated OmpK35 and an Asp137Thr138 duplication in the L3 loop of OmpK36), and carried novel pKpQIL plasmid derivatives (pIT-14159 and pIT-8788, respectively) harboring two copies of the Tn4401a KPC-3-encoding transposon. Plasmid pIT-8788 was a cointegrate of pIT-14159 with a ColE replicon (that was also present in KP-14159) apparently evolved in vivo during infection. pIT-8788 was maintained at a higher copy number than pIT-14159 and, upon transfer to Escherichia coli DH10B, was able to increase the CZA MIC by 32-fold. The present findings provide novel insights about the mechanisms of acquired resistance to CZA, underscoring the role that the evolution of broadly disseminated pKpQIL plasmid derivatives may have in increasing the bla KPC gene copy number and KPC-3 expression in bacterial hosts. Although not self-transferable, similar elements, with multiple copies of Tn4401 and maintained at a high copy number, could mediate transferable CZA resistance upon mobilization.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  CAZ-AVI; KPC; Tn4401; avibactam; carbapenem-resistant Enterobacterales; carbapenemase; double copy; porin alterations

Mesh:

Substances:

Year:  2020        PMID: 31964792      PMCID: PMC7179273          DOI: 10.1128/AAC.01816-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

1.  MgrB inactivation is a common mechanism of colistin resistance in KPC-producing Klebsiella pneumoniae of clinical origin.

Authors:  Antonio Cannatelli; Tommaso Giani; Marco Maria D'Andrea; Vincenzo Di Pilato; Fabio Arena; Viola Conte; Kyriaki Tryfinopoulou; Alkiviadis Vatopoulos; Gian Maria Rossolini
Journal:  Antimicrob Agents Chemother       Date:  2014-07-14       Impact factor: 5.191

2.  Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam.

Authors:  I Galani; A Antoniadou; I Karaiskos; K Kontopoulou; H Giamarellou; M Souli
Journal:  Clin Microbiol Infect       Date:  2019-03-28       Impact factor: 8.067

Review 3.  The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace.

Authors:  Latania K Logan; Robert A Weinstein
Journal:  J Infect Dis       Date:  2017-02-15       Impact factor: 5.226

4.  Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in blaKPC-2-Harboring Klebsiella pneumoniae Sequence Type 307 Isolates.

Authors:  Marla J Giddins; Nenad Macesic; Medini K Annavajhala; Stephania Stump; Sabrina Khan; Thomas H McConville; Monica Mehta; Angela Gomez-Simmonds; Anne-Catrin Uhlemann
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

5.  Mutations in blaKPC-3 That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum β-Lactamases.

Authors:  Ghady Haidar; Cornelius J Clancy; Ryan K Shields; Binghua Hao; Shaoji Cheng; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

6.  An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.

Authors:  Aurora García-Fernández; Vivi Miriagou; Costas C Papagiannitsis; Alessandra Giordano; Mario Venditti; Carlo Mancini; Alessandra Carattoli
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

7.  Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.

Authors:  P Zhang; Q Shi; H Hu; B Hong; X Wu; X Du; M Akova; Y Yu
Journal:  Clin Microbiol Infect       Date:  2019-09-05       Impact factor: 8.067

8.  FIM-1, a new acquired metallo-β-lactamase from a Pseudomonas aeruginosa clinical isolate from Italy.

Authors:  Simona Pollini; Simona Maradei; Patrizia Pecile; Giuseppe Olivo; Francesco Luzzaro; Jean-Denis Docquier; Gian Maria Rossolini
Journal:  Antimicrob Agents Chemother       Date:  2012-10-31       Impact factor: 5.191

9.  Epidemic diffusion of KPC carbapenemase-producing Klebsiella pneumoniae in Italy: results of the first countrywide survey, 15 May to 30 June 2011.

Authors:  T Giani; B Pini; F Arena; V Conte; S Bracco; R Migliavacca; A Pantosti; L Pagani; F Luzzaro; G M Rossolini
Journal:  Euro Surveill       Date:  2013-05-30

10.  Population structure of KPC carbapenemase-producing Klebsiella pneumoniae in a long-term acute-care rehabilitation facility: identification of a new lineage of clonal group 101, associated with local hyperendemicity.

Authors:  Fabio Arena; Vincenzo Di Pilato; Federica Vannetti; Laura Fabbri; Alberto Antonelli; Marco Coppi; Roberto Pupillo; Claudio Macchi; Gian Maria Rossolini
Journal:  Microb Genom       Date:  2020-01
View more
  21 in total

1.  Resistance to Ceftazidime/Avibactam plus Meropenem/Vaborbactam When Both Are Used Together Is Achieved in Four Steps in Metallo-β-Lactamase-Negative Klebsiella pneumoniae.

Authors:  Punyawee Dulyayangkul; Edward J A Douglas; Filip Lastovka; Matthew B Avison
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

2.  KPC-53, a KPC-3 Variant of Clinical Origin Associated with Reduced Susceptibility to Ceftazidime-Avibactam.

Authors:  Vincenzo Di Pilato; Noemi Aiezza; Valentina Viaggi; Alberto Antonelli; Luigi Principe; Tommaso Giani; Francesco Luzzaro; Gian Maria Rossolini
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

Review 3.  Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations: The "Price of Progress".

Authors:  Krisztina M Papp-Wallace; Andrew R Mack; Magdalena A Taracila; Robert A Bonomo
Journal:  Infect Dis Clin North Am       Date:  2020-09-30       Impact factor: 5.982

4.  Outbreak of IncX8 Plasmid-Mediated KPC-3-Producing Enterobacterales Infection, China.

Authors:  Lan Chen; Wenxiu Ai; Ying Zhou; Chunyang Wu; Yinjuan Guo; Xiaocui Wu; Bingjie Wang; Lulin Rao; Yanlei Xu; Jiao Zhang; Liang Chen; Fangyou Yu
Journal:  Emerg Infect Dis       Date:  2022-07       Impact factor: 16.126

5.  The Rapid Emergence of Ceftazidime-Avibactam Resistance Mediated by KPC Variants in Carbapenem-Resistant Klebsiella pneumoniae in Zhejiang Province, China.

Authors:  Congcong Liu; Yuchen Wu; Ling Huang; Yanyan Zhang; Qiaoling Sun; Jiayue Lu; Yu Zeng; Ning Dong; Chang Cai; Zhangqi Shen; Gongxiang Chen; Rong Zhang
Journal:  Antibiotics (Basel)       Date:  2022-05-30

6.  Progressive Development of Cefiderocol Resistance in Escherichia coli During Therapy is Associated With an Increase in blaNDM-5 Copy Number and Gene Expression.

Authors:  Patricia J Simner; Heba H Mostafa; Yehudit Bergman; Michael Ante; Tsigereda Tekle; Ayomikun Adebayo; Stephan Beisken; Kathryn Dzintars; Pranita D Tamma
Journal:  Clin Infect Dis       Date:  2022-08-24       Impact factor: 20.999

7.  Detection of poxtA2, a Presumptive poxtA Ancestor, in a Plasmid from a Linezolid-Resistant Enterococcus gallinarum Isolate.

Authors:  Ilaria Baccani; Alberto Antonelli; Vincenzo Di Pilato; Marco Coppi; Tiziana Di Maggio; Michele Spinicci; Ana Liz Villagran; Carmen Revollo; Alessandro Bartoloni; Gian Maria Rossolini
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

8.  KPC-39-Mediated Resistance to Ceftazidime-Avibactam in a Klebsiella pneumoniae ST307 Clinical Isolate.

Authors:  Agnès B Jousset; Saoussen Oueslati; Cécile Emeraud; Rémy A Bonnin; Laurent Dortet; Bogdan I Iorga; Thierry Naas
Journal:  Antimicrob Agents Chemother       Date:  2021-10-04       Impact factor: 5.191

9.  Evolutionary Trajectories toward Ceftazidime-Avibactam Resistance in Klebsiella pneumoniae Clinical Isolates.

Authors:  Alessandra Carattoli; Gabriele Arcari; Giulia Bibbolino; Federica Sacco; Dario Tomolillo; Federica Maria Di Lella; Maria Trancassini; Luigi Faino; Mario Venditti; Guido Antonelli; Giammarco Raponi
Journal:  Antimicrob Agents Chemother       Date:  2021-08-02       Impact factor: 5.191

10.  First IncHI2 Plasmid Carrying mcr-9.1, blaVIM-1, and Double Copies of blaKPC-3 in a Multidrug-Resistant Escherichia coli Human Isolate.

Authors:  Serena Simoni; Marina Mingoia; Andrea Brenciani; Maria Carelli; Maria M Lleò; Giovanni Malerba; Carla Vignaroli
Journal:  mSphere       Date:  2021-05-28       Impact factor: 4.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.